Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Cypress' agreed to a $6.50 per share cash offer by Ramius and Royalty to acquire the 90.1% of Cypress that Ramius does not already own. Ramius said on Dec. 14 that Cypress rejected a $6 per share offe...